Medtronic’s BrainSense adaptive DBS system wins TIME recognition
Medtronic has announced that its BrainSense Adaptive Deep Brain Stimulation (aDBS) system has been named to TIME magazine’s 2025 Best Inventions list. The technology represents the world’s first closed-loop DBS system designed for people living with Parkinson’s disease, marking what the company describes as the largest commercial launch of brain-computer interface (BCI) technology to date.
Real-time personalisation through brain signal detection
The BrainSense Adaptive technology enhances Medtronic’s Percept DBS neurostimulators by personalising therapy based on a patient’s brain activity in real time, substantially reducing the need for manual stimulation adjustments. The system leverages more than 20 years of development, incorporating exclusive BrainSense technology capable of detecting, capturing and classifying different brain signals.
“Medtronic BrainSense Adaptive Deep Brain Stimulation marks a new era in neuromodulation and the use of therapeutic brain-computer interface technology to restore human health,” TIME editors stated in their recognition of the device.
Clinical evidence supports adaptive approach
The pivotal ADAPT-PD study, recently published in JAMA Neurology, demonstrated clinical effectiveness, long-term safety and patient preference for the adaptive therapy. The system received both CE Mark and US FDA approval earlier this year, with more than 1,000 patients worldwide already receiving the adaptive therapy.
Paolo Di Vincenzo, president of the Neuromodulation business at Medtronic, commented: “This groundbreaking technology represents intentional innovation that responds to a patient’s changing needs, equips clinicians with unparalleled insights, and sets a new standard for DBS therapy.”
Addressing global Parkinson’s burden
With over 10 million people living with Parkinson’s disease globally, the adaptive system addresses a significant clinical need. Whilst no cure currently exists, Medtronic’s DBS therapy has been transforming lives for more than 30 years. Since 1987, the company has served more than 200,000 patients with movement disorders and other indications across more than 70 countries.
The BrainSense technology positions therapeutic BCI integration at the forefront of DBS therapy development. The sensing feature of the Percept PC and Percept RC system enables chronically recorded bioelectric data collection, providing clinicians with objective information regarding patient clinical status.
TIME’s annual Best Inventions list has recognised transformative products, software and services for over two decades. This year’s honourees span categories including artificial intelligence, immersive technology, accessibility, logistics and healthcare, with entries assessed by TIME’s editors on impact, innovation and success.
- For more information, visit: medtronic.com
